Sionna’s medicine didn’t have a meaningful additive impact when combined with Vertex’s top-selling Trikafta, surprising ...

The company's latest launch in this field, Alyftrek, can be taken once daily -- versus twice a day for the one before that.

Vertex Pharmaceuticals' revenue from its cystic fibrosis franchise grew 10% quarter-on-quarter. Click here to see why VRTX ...

Aug 10 (Reuters) - Sionna Therapeutics said on Monday it would stop developing its experimental drug as an addition to standard treatment for a type of genetic disorder after it failed to show a ...

Patients will get new medications if we align incentives to make the moral choice profitable.

Cystic fibrosis investors came to learn a harsh lesson on August 10 about how concentrated a market can be: Sionna Therapeutics, Inc. (NASDAQ:SION) shares fell more than 90% following a key trial ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Sionna Therapeutics said Monday that its ...

<?xml encoding="utf-8" ?> Clinical-stage biopharmaceutical company Sionna Therapeutics Inc. SION announced topline clinical ...

Vertex Pharmaceuticals on Monday raised the upper end of its annual revenue forecast, banking on robust demand for its cystic ​fibrosis treatments.

Vertex Pharmaceuticals raised its guidance for the year as it expects sales growth for its cystic fibrosis therapies to continue. The biotechnology company said Monday it now expects revenue of $13.1 ...

Sionna Therapeutics has axed a cystic fibrosis add-on program after flunking a phase 2 trial, eliminating a would-be challenger to Vertex Pharmaceuticals’ empire. The biotech plans to “take actions to ...